Sanofi Labels Biosimilars 'Enormous Distraction'
French Player Has A Small Biosimilar Presence
While in possession of a token biosimilar portfolio and pipeline, Sanofi has made it clear that its R&D dollars are unlikely to be spent on biosimilars, six months after reshaping its pipeline by exiting diabetes and cardiovascular diseases research.
You may also be interested in...
In the month ahead, Mylan and Upjohn will at last begin to make final preparations for their proposed combination while second-quarter results are expected from large cap companies including Novartis’ Sandoz, Amgen, Biogen and Pfizer.
Mylan and Biocon have received FDA approval for their Semglee insulin glargine product, with a path to market seemingly clear after Mylan emerged victorious in several recent patent-litigation challenges. Meanwhile, the firm continues to strive towards an interchangeability designation that would make it a much more valuable opportunity.
Sanofi has received a positive opinion from the CHMP for its insulin aspart biosimilar rival to NovoRapid. Meanwhile, Accord and Janssen-Cilag have also received positive opinions for generics and hybrid medicines.